阿司匹林使用与痴呆风险之间的关联:系统性审查和元分析
Tao Tao1, Guohua Feng1, Yuanyuan Fang2
1Department of Geriatric Psychiatry, Shaoxing No. 7 People's Hospital, Shaoxing, China.
European geriatric medicine
|October 23, 2023
概括
低剂量阿司匹林并不能降低痴呆症或阿尔茨海默病 (AD) 的风险. 这次审查发现,即使在预防性使用的情况下,也没有显著的影响. 需要进一步的高质量研究来证实这些发现对于痴呆症预防策略.
科学领域:
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
- 药理学 药理学是指药理学的学科.
背景情况:
- 痴呆症和阿尔茨海默病 (AD) 是全球主要的健康问题,没有有效的治疗方法.
- 预防策略或预防对于管理这些神经退行性疾病的发病率上升至关重要.
- 以前的研究表明,低剂量阿司匹林在降低痴呆风险方面具有潜在的益处,但证据仍然有限.
研究的目的:
- 系统地审查和评估关于阿司匹林消费与痴呆和AD发病之间的联系的现有证据.
- 提供关于阿司匹林在痴呆和AD预防中的作用的最新研究结果的摘要.
主要方法:
- 在多个数据库 (PubMed,Embase,Web of Science,PsycINFO,CINAHL) 进行了全面的系统搜索,直到2023年4月.
- 符合条件的研究使用随机效应元分析进行了综合分析,以评估阿司匹林使用与痴呆/AD发病之间的联系.
- 亚组分析专门研究了低剂量阿司匹林 (75-100毫克) 对痴呆和AD发病率的影响.
主要成果:
- 在875项已识别的研究中,有22项符合审查的纳入标准.
- 阿司匹林消费对痴呆症 (HR 1.13) 或阿尔茨海默病 (HR 0.91) 的发病没有统计学上显著的影响.
- 低剂量阿司匹林 (75-100毫克) 也没有显著影响痴呆 (HR 0.96) 或阿尔茨海默病 (HR 0.85) 的发病.
结论:
- 目前的证据表明,使用阿司匹林,包括低剂量,不会降低患痴呆症或阿尔茨海默病的风险.
- 纳入研究的质量被认为是不充分的,随机对照试验数量有限.
- 未来的高质量研究对于确定阿司匹林对痴呆和AD的预防作用至关重要.
相关概念视频
Dementia
120
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
120
Genome-wide Association Studies-GWAS
13.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.5K
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Psychoneuroimmunology: Diabetes and Cancer
31
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
31
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
131
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
131


